CD4 and progressive multifocal leukoencephalopathy: Prior studies have identified that the disease onset is contingent upon a decline in JCV-specific cellular immunity, with CD4+ T-cell count correlating with PML prognosis.10 Although CD4 counts were not tested before rituximab initiation, a progressive decline in CD4+ T-cell and total lymphocyte count was observed.